EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Short-Term Clinical and Biochemical Outcomes of IL-23p19 Inhibitors in Refractory Ulcerative Colitis: A Real-World Case Series

Satohiro Matsumoto, Yurika Imai, Mina Morino, Takaya Miura, Haruka Otake, Takeshi Uehara, Hirosato Mashima

Inflammatory Intestinal Diseases · 09.07.2026 · 11 (1) · 337-344

DOI: 10.1159/000553498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 09.07.2026. Verfasst von Satohiro Matsumoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Jichi Medical University Saitama Medical Center, Saitama, Japan. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

IL-23p19 inhibitors have emerged as therapeutic options for moderate-to-severe ulcerative colitis (UC), but real-world data describing their early clinical use remain limited.

Methods

We conducted a single-center retrospective study of consecutive adults with moderate-to-severe UC who initiated mirikizumab (MIR) (n = 10), risankizumab (RIS) (n = 15), or guselkumab (GUS) (n = 15) between January 2024 and March 2026. Clinical Activity Index (CAI), clinical response, clinical remission, leucine-rich alpha-2 glycoprotein (LRG), and adverse events were assessed over 12 weeks.

Results

The cohort was predominantly treatment-refractory, with prior exposure to biologics or Janus kinase inhibitors in 67–100% of patients. Median CAI decreased from 5.5 to 3.5 with MIR, from 8 to 3 with RIS, and from 7 to 3 with GUS by week 12. Week 12 clinical remission rates were 40%, 67%, and 67%, respectively. Median LRG levels decreased from 15.9 to 14.5 μg/mL, from 13.2 to 10.0 μg/mL, and from 14.4 to 11.1 μg/mL, respectively. Three patients discontinued therapy because of primary non-response: two treated with MIR and one treated with RIS. No serious adverse events occurred.

Conclusion

This 40-patient real-world cohort suggests short-term clinical and biochemical improvement after initiation of IL-23p19 inhibitors in refractory UC, with no serious adverse events observed during the 12-week observation period. These findings should be interpreted as preliminary and hypothesis-generating, and larger prospective studies are warranted to clarify long-term outcomes.

Schlagwörter

Stichwörter der Autor:innen

IL-23p19 inhibitorsLeucine-rich alpha-2 glycoproteinReal-world evidenceRefractory diseaseUlcerative colitis

Autor:innen und Institutionen

  • Department of Gastroenterology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Zitieren

APA

Matsumoto, S., Imai, Y., Morino, M., Miura, T., Otake, H., Uehara, T., & Mashima, H. (2026). Short-Term Clinical and Biochemical Outcomes of IL-23p19 Inhibitors in Refractory Ulcerative Colitis: A Real-World Case Series. Inflammatory Intestinal Diseases, 11(1), 337-344. https://doi.org/10.1159/000553498

Vancouver

Matsumoto S, Imai Y, Morino M, Miura T, Otake H, Uehara T, et al. Short-Term Clinical and Biochemical Outcomes of IL-23p19 Inhibitors in Refractory Ulcerative Colitis: A Real-World Case Series. Inflammatory Intestinal Diseases. 2026;11(1):337-344. doi:10.1159/000553498

BibTeX
@article{Matsumoto2026,
  author = {Matsumoto, Satohiro and Imai, Yurika and Morino, Mina and Miura, Takaya and Otake, Haruka and Uehara, Takeshi and Mashima, Hirosato},
  title = {Short-Term Clinical and Biochemical Outcomes of IL-23p19 Inhibitors in Refractory Ulcerative Colitis: A Real-World Case Series},
  journal = {Inflammatory Intestinal Diseases},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {337--344},
  doi = {10.1159/000553498}
}
Kostenlos starten →